Stock Analysis on Net
Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

$24.99

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity

Paying user area

Try for free

Regeneron Pharmaceuticals Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Regeneron Pharmaceuticals Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Accounts payable
Accrued payroll and related costs
Accrued clinical expenses
Accrued sales-related costs
Income tax-related costs
Other accrued expenses and liabilities
Accrued expenses and other current liabilities
Finance lease liabilities, current portion
Deferred revenue
Current liabilities
Long-term debt
Finance lease liabilities, excluding current portion
Deferred revenue
Other noncurrent liabilities
Noncurrent liabilities
Total liabilities
Preferred Stock, par value $.01 per share; issued and outstanding: none
Class A Stock, convertible, par value $.001 per share
Common Stock, par value $.001 per share
Additional paid-in capital
Retained earnings
Accumulated other comprehensive income (loss)
Treasury Stock, at cost
Stockholders’ equity
Total liabilities and stockholders’ equity

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

The analysis of the financial data reveals several notable trends in the composition of liabilities and stockholders’ equity over the reported periods.

Current liabilities
Current liabilities as a percentage of total liabilities and stockholders’ equity show a declining trend from 15.72% in 2020 to a low of 10.35% in 2023, with a slight increase to 10.45% in 2024. Specific components such as accounts payable, accrued payroll and related costs, accrued clinical expenses, and accrued sales-related costs generally decreased in proportion, suggesting an improvement in short-term obligations management or changes in operational activities affecting these accounts.
Accrued expenses
Accrued expenses and other current liabilities declined from 9.58% in 2020 to 6.69% in 2024, indicating a reduction in obligations that might be short-term in nature. The component "other accrued expenses and liabilities" also decreased steadily from a peak of 3.92% in 2021 to 1.51% in 2024, contributing to this overall decline.
Deferred revenue
Deferred revenue as a current liability slightly decreased from 3.37% in 2020 to 1.66% in 2024, with some fluctuation. The noncurrent deferred revenue portion also remained relatively stable but registered a modest increase towards 2024, potentially reflecting changes in revenue recognition timing.
Long-term liabilities
Long-term debt showed a steady decline from 11.53% in 2020 to 5.26% in 2024, indicating a reduction in long-term borrowing or debt repayment over time. Finance lease liabilities (both current and noncurrent portions) also decreased substantially, pointing to changes in lease obligations or accounting treatment of leases. However, other noncurrent liabilities increased from 2.67% in 2021 to 4.16% in 2024, which may offset some of the reductions in other long-term liabilities.
Total liabilities
Total liabilities as a percentage of total liabilities and stockholders’ equity declined from 35.76% in 2020 to 21.48% in 2023, before a slight rise to 22.26% in 2024. This overall downward trend suggests an improving balance sheet with a relatively reduced debt and obligation burden over the years.
Stockholders’ equity
Stockholders’ equity increased from 64.24% in 2020 to a peak of 78.52% in 2023, then slightly decreased to 77.74% in 2024. Retained earnings showed continuous growth from 63.47% to 83.88%, implying accumulated profitability or retained profits reinvested in the business. Additional paid-in capital exhibited some fluctuations but remained stable around the mid-30% range in the latter years. Treasury stock steadily increased in negative proportion, reaching -40.17% by 2024, which reflects continued share repurchases or treasury stock accounting impacts.
Other comprehensive income
The accumulated other comprehensive income (loss) maintained a minor negative position throughout the periods, ranging from a slight positive 0.17% in 2020 to a negligible negative -0.02% by 2024, indicating minimal impact on overall equity from these components.
General notes
Income tax-related costs appeared only in 2023 and 2024 at negligible proportions, possibly reflecting changes in tax accounting or transitional tax liabilities. The overall composition shift from liabilities toward greater equity proportion suggests strengthening capitalization and potentially lower risk exposure in financial structure.